Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Treatment with the angiotensin II receptor blocker telmisartan delivered greater beneficial effects on biomarkers than non-ARB therapy in hypertensive patients, according to the ATTEMPT-CVD study yesterday. The Japanese study, also published in the European Journal of Preventive Cardiology, showed that telmisartan promoted both smaller increases in plasma brain natriuretic peptide (BNP) and larger decreases in urinary albumin creatinine ratio (UACR).
While it is known that ARBs affect levels of biomarkers such as urinary albumin and BNP, studies measuring biomarkers in hypertensive patients and relating them to cardiovascular events have been rare. In this study Hisao Ogawa and colleagues from Kumamoto University, Japan, investigated the effect of an ARB and non-ARB on biomarker change and the incidence of cardiovascular events in hypertensive patients.
A total of 1228 hypertensive patients aged 40-80 years with at least one other cardiovascular risk factor (diabetes, renal, cerebral or peripheral artery factors) were randomly assigned to receive telmisartan (n = 615) or non-ARB standard treatment (n = 613). Patients were enrolled from 168 institutions throughout Japan.
Results showed that in comparison to baseline UACR changes in the ARB group were significantly steeper than in the non-ARB group (P<0.0010). The increase of plasma BNP over time in the ARB arm was significantly less than for the non-ARB arm. While fewer cardiovascular events occurred among patients in the ARB group, the difference was not statistically significant.
‘Taken together with the finding that there were no significant differences in blood pressure between the ARB and non-ARB groups throughout the treatment, this study provides the first evidence that ARB treatment suppressed an age-associated increase in plasma BNP independently of blood pressure,’ said the authors.
About the European Society of CardiologyThe European Society of Cardiology (ESC) represents more than 90 000 cardiology professionals across Europe and worldwide. Its mission is to reduce the burden of cardiovascular disease in Europe. About ESC Congress 2015ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2015 takes place 29 August to 2 September at ExCel London in London, UK. Access the scientific programme. To access all the scientific resources from the sessions during the congress, visit ESC Congress 365.
© 2017 European Society of Cardiology. All rights reserved